Business Context and Reporting Period
This Form 8-K is a current report filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on April 27, 2020. The registrant is a Delaware corporation with its principal executive offices in South San Francisco, California. The report addresses Item 5.02 regarding the departure of certain officers and the appointment of new officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: Ms. Kristen Gafric resigned as Senior Vice President, Legal and Administration, and Secretary, effective April 27, 2020. Her last day of employment is May 1, 2020.
- Appointment: Caryn G. McDowell will join the Company as Chief Legal and Administrative Officer and Corporate Secretary, effective May 11, 2020.
- Compensation: A separation agreement was entered into with Ms. Gafric providing cash severance equal to six months of her current annual base salary, contingent upon a general release of claims.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. The primary contingency noted is the execution of the Separation Agreement with the departing officer, the full text of which is to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2020.
Investor Verification Checklist
- Verify the exact terms of the Separation Agreement with Ms. Gafric in the upcoming Form 10-Q filing.
- Confirm the start date and role responsibilities of the new Chief Legal and Administrative Officer, Caryn G. McDowell.
- Note that the company name in the metadata request (Quince Therapeutics) differs from the registrant in the filing (Cortexyme, Inc.).